Myomo, INC

Myomo, Inc. filed an amendment to its Form 8-K to correct exhibit labeling and confirm shareholder approvals for director elections, executive compensation, auditor ratification, stock plan amendments, and charter changes.

Myomo stockholders approved an increase in authorized common stock to 100 million shares and expanded the 2018 equity incentive plan.

Myomo, Inc. announced the appointment of Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026, bringing extensive experience in investment banking and corporate governance.

Myomo, Inc. has appointed healthcare and capital markets veteran William J. Febbo to its Board of Directors to support strategic scaling and investor relations.

Myomo's CEO and CFO voluntarily reduced their 2026 base salaries by 10% in exchange for restricted stock units valued at 115% of the foregone amount.

Myomo, Inc. announced a new $17.5 million debt facility and reported third-quarter 2025 financial results, showing revenue growth but increased net losses and a decline in gross margin.

Myomo, Inc. announced its second quarter 2026 financial results, showcasing a 21% increase in revenue and a significant improvement in gross margins, though net losses persist.

Myomo Inc. reported a 3% increase in Q1 2026 revenue to $10.11 million, but net loss widened to $3.01 million, impacted by increased operating expenses and derivative liability revaluation.

Myomo, Inc. reported increased revenue for Q3 and YTD 2025, but also significantly wider net losses and higher cash burn, while securing $17.5 million in new committed debt capital.

Myomo, Inc. reported a significant increase in net loss for the second quarter and first half of 2025 despite substantial revenue growth, driven by higher operating expenses and a decline in gross margin.

Myomo Inc. reports a significant increase in first-quarter revenue, driven by growth in its direct billing channel and higher average selling prices, despite ongoing net losses.

Myomo Inc. saw a significant increase in product revenue and gross profit in the third quarter of 2024, driven by Medicare reimbursements, and anticipates achieving operating cash flow breakeven by the end of the year.

Myomo, Inc. reports increased product revenue and outlines strategic plans for 2025, including expanding its direct billing channel and O&P partnerships.

Myomo, Inc. reports a 20% increase in product revenue for 2023 and anticipates achieving cash flow breakeven by the fourth quarter of 2024, driven by Medicare reimbursement changes.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., reported multiple transactions in common stock on August 7, 2026.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., reported multiple transactions in common stock on August 7, 2026.

Paul R Gudonis, Chief Executive Officer and a Director of Myomo, Inc., received 146,909 shares of common stock on August 7, 2026.

David A Henry, Chief Financial Officer of Myomo, Inc., reported multiple transactions in common stock on August 7, 2026.

David A Henry, Chief Financial Officer of Myomo, Inc., reported multiple transactions in common stock on July 10, 2026.

Paul R Gudonis, Chief Executive Officer and a Director of Myomo, Inc., received 10,454 shares of common stock on July 10, 2026.

Myomo, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 25, 2026, to address key corporate governance and equity plan matters, including a significant increase in authorized common stock.

Myomo, Inc. will hold its annual stockholders meeting virtually on June 11, 2025, to elect a director, ratify the appointment of CBIZ CPAs P.C. as the independent auditor, and transact other business.

Myomo, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 11, 2025, to elect a director, ratify the appointment of its accounting firm, and transact other business.

Myomo, Inc. will hold its annual stockholders meeting on June 5, 2024, to elect directors and ratify the appointment of its independent auditor.

Myomo, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to elect directors and ratify the appointment of its independent auditor.

Horton Capital Partners has acquired a 6% stake in Myomo, Inc. and secured a board seat for Joseph M. Manko, Jr.

Horton Capital Partners has acquired a 5.1% stake in Myomo, Inc. and submitted a shareholder proposal to declassify the company's Board of Directors for annual elections.

Rosalind Advisors, Inc. and its affiliates have jointly filed a Schedule 13G/A, reporting a beneficial ownership of 9.9% of Myomo, Inc.'s common stock.

Rosalind Advisors and Master Fund confirm a passive beneficial ownership of approximately 9.99% in Myomo, Inc., primarily through common stock and pre-funded warrants subject to blocker provisions.

Rosalind Advisors and affiliated entities filed an amended Schedule 13G/A for Myomo, Inc., clarifying beneficial ownership of 3,790,788 common shares, representing 9.99% due to warrant blocker provisions.

Orin Hirschman and AIGH Capital Management LLC have filed an amended Schedule 13G, disclosing beneficial ownership of 1.3% of Myomo, Inc.'s common stock.

Rosalind Advisors and affiliated entities have filed an amended Schedule 13G/A, disclosing their beneficial ownership in Myomo, Inc. at 9.51% of common stock.

Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon have filed an amended Schedule 13G/A, disclosing a 9.9% beneficial ownership stake in Myomo, Inc., though blocker provisions prevent immediate exercise of pre-funded warrants that would push ownership above 9.99%.